Inlyta
My Prescription
Payment
Select pharmacy
$23,048.34
Print or send this coupon to your phone
AlbertsonsPowered byAbout Inlyta
Drug Details
Axitinib, marketed as Inlyta, is an oral medication primarily prescribed for the treatment of advanced kidney cancer, also known as renal cell carcinoma. It can be used alone or in combination with immunotherapy drugs such as Keytruda (pembrolizumab) and Bavencio (avelumab). Axitinib belongs to a group of cancer treatments called tyrosine kinase inhibitors, specifically targeting VEGFR proteins. These proteins play a role in the development of blood vessels that supply nutrients to tumors. By inhibiting these proteins, axitinib effectively hinders the tumor's blood supply, thereby slowing or halting cancer progression. Common side effects may include diarrhea, fatigue, and high blood pressure. Always discuss with your healthcare provider before starting new medications to ensure safety and efficacy.
Price history for Inlyta
60 Tablets, 5MG
Average retail price for Inlyta
Average SaveHealth price for Inlyta
Our price history data is based on aggregated prescription data collected from participating pharmacies in America. Our prescription data updates daily to reflect the latest price changes. If you notice a missing data point, it means there wasn't sufficient data available to generate a monetary value for that date.
*Retail prices are based on pharmacy claims data, and may not be accurate when we don't have enough claims.
Inlyta dosage forms
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 1MG | 180 Tablets | $23,048.34 | $128.05 |
| 5MG | 60 Tablets | $23,048.34 | $384.14 |
Inlyta FAQs
Inlyta is used to treat advanced renal cell carcinoma, which is a type of kidney cancer.
Inlyta (axitinib) may cause weight loss as a side effect in some patients. It is important for individuals taking Inlyta to monitor their weight and report any significant changes to their healthcare provider.
Side effects of INLYTA (axitinib) can start soon after beginning treatment, often within the first few days to weeks. However, the onset and severity of side effects can vary from person to person. It is important for patients to monitor for any adverse effects and report them to their healthcare provider promptly.
INLYTA (axitinib) is neither chemotherapy nor immunotherapy. It is a targeted therapy, specifically a tyrosine kinase inhibitor, used in the treatment of advanced renal cell carcinoma.
While taking INLYTA (axitinib), it is advisable to avoid grapefruit and grapefruit juice. Grapefruit can interfere with the metabolism of the medication, potentially increasing its levels in the blood and leading to an increased risk of side effects. It is always best to consult with a healthcare provider for personalized dietary recommendations while on this medication.